HemaSure
This article was originally published in The Gray Sheet
Executive Summary
Private placement of 3.7 mil. shares nets $26 mil. to fund a two-year capacity expansion project for the firm's r/LS red blood cell filtration system. The expansion is anticipated to result in a greater-than-ten-fold increase in production capability in order to meet demand for leukoreduced blood products. The project will commence in the second quarter and further the American Red Cross goal of 100% leukoreduction by the end of 2000